Showing: 1 - 2 of 2 RESULTS

Wisconsin restaurant installs virus-killing lights in its dining room, bar area

A Wisconsin restaurant is installing lights that reportedly kill airborne viruses

The Blind Horse Restaurant & Winery in Kohler, Wisconsin, is reportedly the first restaurant in the U.S. to install far-UVC light technology, according to a press release. 

Healthe, Inc., a Florida-based company, made the lights — called “Healthe Space” lights — which “provide real-time mitigation of harmful pathogens and viruses,” the release said.

According to the company, the lights are mounted on the ceiling and give off general light as well as “far-UVC 222 sanitizing light to clean air and surfaces.”

TACO SHOP EMPLOYEE LOSES JOB AFTER TWEET ABOUT TAMPERING WITH CHARLESTON CITY COUNCIL MEMBER’S FOOD

Eighteen of the Healthe Space lights are being installed throughout the restaurant, in the dining and bar areas, as well as in other buildings on the property.  

CHICAGO PICKS WINNING DESIGNS FOR OUTDOOR DINING SOLUTIONS IN WINTER

“Of utmost importance to us is that we provide a safe environment so our guests and employees have the opportunity to feel a sense of normalcy and well-being that has been shaken by COVID-19,” Thomas Nye, The Blind Horse’s general manager and master winemaker, said in a statement. 

RESERVATION AT SINGAPORE AIRLINES’ RESTAURANT A380, WHERE GUESTS EAT IN A GROUNDED JET, SELL OUT IN HALF HOUR

“Real time mitigation of the virus has been our goal since this crisis began,” Nye added. “The suite of safety protocols and technology that we are installing is extensive and unprecedented in our industry. Our customers have come to expect The Blind Horse to be a leader, and we are proud to be at the forefront in utilizing this technology in the restaurant and winery industry.”   

A restaurant in Wisconsin is installing virus-killing lights in its dining room. (iStock)

A restaurant in Wisconsin is installing virus-killing lights in its dining room. (iStock)

CLICK HERE TO GET THE FOX NEWS APP

In June, researchers from Columbia University Irving Medical Center found that far-UVC light kills the coronavirus safely, without harming human tissue. 

According to the study, which was published in “Scientific Reports” — 99.9% of two coronaviruses that were exposed to far-UVC light were killed.

CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER

“The Blind Horse is exhausting all procedures, products and processes to create a safer hospitality experience and to lessen the impact of our current climate,” Nye said. “Everyone is seeking a positive way forward to inspire our struggling industry. The cost, especially for a small business, is daunting. Our customers and staff appreciate all the time, money and effort to create a safer environment.”

FOLLOW US ON FACEBOOK FOR MORE FOX LIFESTYLE NEWS

Aside from the new lights, The Blind Horse has also implemented other health technologies including ultraviolet lighting treatments, improved air systems and ozone treatments at night. Servers at The Blind Horse also wear copper woven masks that have an additional layer of “antimicrobial protection,” the release said.

Source Article

Xellia Pharmaceuticals Launches New Doses of VANCO READYTM (Ready-to-use Room Temperature Premixed Vancomycin Injection Bags)

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.

The VANCO READYTM availability will now cover all relevant doses from 500 mg to 2 g in 250 mg increments.

The availability of 750 mg in 150 mL, 1.25 g in 250 mL and 1.75 g in 350 mL are joining our range of presentations launched in 2019 – 500 mg in 100 mL, 1 g in 200 mL, 1.5 g in 300 mL and 2 g in 400 mL.

VANCO READYTM should not be administered during pregnancy, please see boxed warning below.

Carl-Åke Carlsson, Xellia’s CEO said: “With all seven VANCO READYTM presentations, Xellia can service the majority of needs of healthcare professionals in the vancomycin injection market. The success of our first four products has resulted in over 2,000 US institutions using VANCO READYTM. Since our announcement of approval, we have already seen strong interest and demand for the new codes from healthcare professionals on the basis of the product being room temperature and the most ready to use product available.”

Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of septicemia (sepsis), infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections.

Craig Boyd, Xellia’s North American President said: “One of the uses for Vancomycin in the US is in the treatment of sepsis. The timely initiation of effective antibiotic treatments is universally recognized as a key intervention in the management of this life-threatening state as well as other infections. We are pleased to have been able to expand the range of doses available to clinicians, broadening their options to aid rapid and effective treatment.”

In the United States, sepsis is the third leading cause of death after heart disease and cancer, affecting more than 1.7 million people and killing more than 270,000 people within a single year1.

“Our room-temperature-stable VANCO READYTM premix has been critical in providing a truly ready Vancomycin Injection product. It aligns with recommendations from US agencies – such as the American Society of Hospital Pharmacists (ASHP), Institute for Safe Medication Practices (ISMP) and Joint Commission – to use manufacturer-prepared products as part of safe medication practice. We will continue to build on this success and focus on our ready-to-use product pipeline and partnerships during 2020.”

– Ends –

References

1 Rhee, C. et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318, 1241–1249 (2017).

Full prescribing information for Vancomycin Injection Premix RTU can be found at www.vancoready.com and www.xellia.com/us

About Vancomycin Injection

Vancomycin Injection, Ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature (up to 25 °C) for 16